Axonics, Inc. (NASDAQ:AXNX) Shares Acquired by Citigroup Inc.

Citigroup Inc. lifted its holdings in Axonics, Inc. (NASDAQ:AXNX) by 7.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 647,152 shares of the company’s stock after buying an additional 46,841 shares during the period. Citigroup Inc. owned about 1.27% of Axonics worth $45,042,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Charles Schwab Investment Management Inc. raised its position in Axonics by 1.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 419,985 shares of the company’s stock valued at $29,231,000 after buying an additional 6,115 shares during the period. Intech Investment Management LLC acquired a new position in Axonics during the third quarter valued at $907,000. Alpine Associates Management Inc. raised its position in Axonics by 3.3% during the third quarter. Alpine Associates Management Inc. now owns 2,178,157 shares of the company’s stock valued at $151,600,000 after buying an additional 69,286 shares during the period. Entropy Technologies LP acquired a new position in Axonics during the third quarter valued at $395,000. Finally, Wolverine Asset Management LLC raised its position in Axonics by 7.8% during the third quarter. Wolverine Asset Management LLC now owns 45,491 shares of the company’s stock valued at $3,166,000 after buying an additional 3,300 shares during the period. 99.48% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reissued a “hold” rating on shares of Axonics in a research report on Friday, November 8th. Eight investment analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $71.00.

Insider Buying and Selling at Axonics

In other news, CFO Kari Leigh Keese sold 2,961 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $69.41, for a total transaction of $205,523.01. Following the completion of the sale, the chief financial officer now owns 40,362 shares in the company, valued at approximately $2,801,526.42. This represents a 6.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.85% of the company’s stock.

Axonics Price Performance

Shares of NASDAQ AXNX opened at $70.98 on Monday. The business’s 50-day moving average price is $70.09 and its two-hundred day moving average price is $68.73. Axonics, Inc. has a one year low of $55.09 and a one year high of $71.05. The company has a market capitalization of $3.63 billion, a P/E ratio of -591.45 and a beta of 0.82.

Axonics Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.